Patents by Inventor Jay M. Short

Jay M. Short has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141035
    Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 2, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • Publication number: 20240117067
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20240092901
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: August 29, 2023
    Publication date: March 21, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11897959
    Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: February 13, 2024
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11879011
    Abstract: A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: January 23, 2024
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11851499
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: December 26, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Patent number: 11834472
    Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 5, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • Publication number: 20230374702
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Application
    Filed: June 27, 2023
    Publication date: November 23, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230332135
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 19, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11773509
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 3, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11718844
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 8, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230242662
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to CD46 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CD46 protein. Immunoconjugages, pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: June 15, 2021
    Publication date: August 3, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING
  • Publication number: 20230235054
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to Nectin-4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Nectin-4 protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 27, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING, Haizhen LIU, Ana Paula CUGNETTI
  • Publication number: 20230192858
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 22, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20230183679
    Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 15, 2023
    Applicant: BioAtla, Inc
    Inventor: Jay M. Short
  • Patent number: 11639365
    Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: May 2, 2023
    Assignee: BioAtla, Inc.
    Inventor: Jay M. Short
  • Publication number: 20230109218
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to HER2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to HER2 protein and multi-specific antibodies that bind to HER2 protein and CD3.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 6, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen Chang
  • Publication number: 20230072955
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.
    Type: Application
    Filed: January 23, 2021
    Publication date: March 9, 2023
    Applicants: Exuma Biotech Corp, BioAtla, Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Patent number: 11584927
    Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: February 21, 2023
    Assignee: BioAtla, Inc.
    Inventor: Jay M. Short
  • Patent number: 11542332
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: January 3, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang